Teva launches generic Brinzolamide ophthalmic suspension in US

The product, which is a generic version of Azopt ophthalmic suspension, is developed and manufactured by the Mumbai-based drug firm at its Goa facility for Teva.

42
Ad Marketing
Picture: Pixabay

Last Updated on March 11, 2021 by The Health Master

Indoco Remedies on Tuesday said Teva Pharmaceuticals has launched Brinzolamide ophthalmic suspension used in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma in the United States.

The product, which is a generic version of Azopt ophthalmic suspension, is developed and manufactured by the Mumbai-based drug firm at its Goa facility for Teva.

Brinzolamide ophthalmic suspension (1 per cent) works by decreasing the amount of fluid within the eye.

As per the IQVIA data, as of December 2020, the US market size of this product stood at USD 184 million.

“This first-to-market generic version of AZOPT (Brinzolamide Ophthalmic Suspension 1 per cent, developed by Indoco) in the US brings in an enormous opportunity for the company to serve the patients with a generic option,” Indoco Remedies MD Aditi Kare Panandikar said in a statement.

The generic product gives the company satisfaction to be a part of the journey in developing and securing approval from the US regulators for such complex generic products, ensuring access to affordable and quality medicines, she added.

Headquartered in Mumbai, Indoco employs over 5,500 people across nine manufacturing facilities and has a presence in 55 countries.


Also read:

NATCO gets USFDA nod for Breast Cancer treatment drug

Kite gets USFDA nod for drug to treat Follicular Lymphoma

Shilpa Medicare gets USFDA tentative nod for drug for Arthritis

Aleor Dermaceuticals gets USFDA nod for Testosterone Gel

Unichem gets USFDA nod for Guanfacine Tablets

Cipla gets US FDA approval for generic drug for Migraine

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner